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The study of regulatory non-coding RNAs 
has deepened our understanding of can-
cer on the molecular and clinical front. 
MicroRNAs, which encompass over 1000 
short, endogenous nucleic acids, include 
important candidates that drive carcino-
genesis. In this discussion, we review the 
literature on miR-135b, purporting its role 
as an oncogene in multiple cancers, and we 
highlight STAT3 inhibition as a potential 
therapeutic strategy mediated by miR-
135b and demonstrate particular clinical 
relevance to colon cancer.
MicroRNA-135b (miR-135b) 
OveRexpRessiON ANd ONcOgeNic 
BehAviOR
miR-135b levels are elevated in a variety 
of cancers including breast, non-small cell 
lung cancer (NSCLC), prostate, and colon 
(1–3). Microarray analysis and quantita-
tive reverse transcription-PCR (qRT-PCR) 
studies in NSCLC have demonstrated that 
miR-135b upregulation is far more robust 
in highly invasive lines compared to the 
less invasive. Overexpression of miR-135b 
conferred an increased tumorigenic ability 
to the relatively benign CL1-0 cells, result-
ing in more than a fourfold greater tumor 
burden in xenograft mouse models. In vivo, 
stable expression of a miR-135b antagonist 
decreased the number of metastatic tumor 
nodules in mice injected with highly inva-
sive CL1-5-F4 cells shown to have high lev-
els of miR-135b (4).
Clinically, high levels of miR-135b in 
lung cancer specimens significantly cor-
related with decreased overall survival (4). 
The investigators demonstrated that miR-
135b suppresses key components of the 
Hippo pathway, a serine-threonine kinase 
pathway studied extensively in Drosophila 
melanogaster that plays a role in inhibi-
tion of overgrowth, regulation of cell divi-
sion, and apoptosis. Mammalian orthologs 
within the Hippo pathways include LATS2 
and LZTS1, which were identified as tar-
gets of miR-135b. Downregulation of 
LATS2 and LZTS1 and consequent nuclear 
localization of the transcriptional activa-
tor TAZ in patients with high miR-135b 
levels correlated with poor overall survival 
(4). Clinically, deregulation of this pathway 
also appears to be an important driver of 
hepatocellular and cholangiocarcinoma, 
although, to our knowledge, its regulation 
has not been linked to miR-135b in the set-
ting of liver disease (5).
Microarray analysis and qRT-PCR also 
demonstrate that miR-135b levels are 
more than twofold higher in head and 
neck squamous cell carcinoma (HNSCC) 
in an orthotopic mouse model compared 
to controls (6). Parallel to the findings in 
lung cancer, in vitro studies with HNSCC 
also demonstrate that miR-135b overex-
pression confers an invasive phenotype – 
cells expressing miR-135b mimic displayed 
increased colony formation, cell migra-
tion, and proliferation. miR-135b mimics 
also induced increased tube formation of 
human umbilical vein endothelial cells, 
providing in vitro support for its role is 
promoting angiogenesis.
Investigators subsequently identified 
upregulation of hypoxia inducible factor 
1 alpha (HIF-1α) and vascular endothelial 
growth factor A (VEGFA), which is a down-
stream target of HIF-1α, as a consequence 
of miR-135b overexpression. In vitro data 
suggests that miR-135b decreases avail-
able factor inhibiting HIF (FIH), which is 
also known as HIF-1α subunit inhibitor 
(HIFIAN). The Tgfbr1/Pten 2c knockout 
mice serving as the orthotopic HNSCC 
model in this study demonstrated decreased 
levels of Fih mRNA and protein in tongue 
squamous cell carcinoma compared to sur-
rounding tongue epithelium and compared 
to control mice. These findings correlated 
with elevated levels of miR-135b and 
Hif-1α mRNA. When HNSCC cell lines 
were transfected with a miR-135b mimic, 
a corresponding increase in protein levels 
of HIF-1α and decrease in FIH was elicited.
Immunofluorescence and Western 
blot analysis demonstrated parallel cor-
relation between elevated miR-135b levels 
and decreased FIH signal in the Tgfbr1/
Pten 2cKO mice. Nuclear localization of 
HIF-1α and VEGFA signals were signifi-
cantly increased in mice with elevated miR-
135b levels. Finally, microvessel density of 
HNSCC in Tgfrb1 knockout mice was over 
fourfold greater compared to control Pten 
knockout HNSCC, providing in vivo data 
consistent with miR-135b promotion of 
angiogenesis.
Studies in colon cancer also demon-
strate a distinct increase in expression of 
miR-135b in both adenomas and carci-
nomas compared to normal epithelium 
(1, 7, 8). Its role in driving adenoma to 
carcinoma progression, however, has not 
been established. Nonetheless, the pro-
gressive increase in miR-135b expression 
from normal tissue to polyp to carcinoma, 
suggests that miR-135b deregulation is an 
early event that is amplified with increasing 
dysplasia. Nagel et al. support this hypoth-
esis by demonstrating adenomatous poly-
posis coli (APC) to be an important target 
of miR-135b (7). On a genomic level, it is 
known that biallelic mutations in the APC 
gene are the primary initiating events in 
the adenoma to carcinoma sequence 
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to activate anti-apoptotic pathways and 
proliferative behaviors in a variety of can-
cers (12, 14).
If miR-135b expression is pervasively 
regulated by STAT3 in a variety of can-
cer types, it may perform a key exchange 
between the tumor microenvironment 
to inhibition of tumor suppressors. This 
extracellular ligand stimulation may also 
explain differences that may be observed in 
the role of miR-135b between one organ 
system and another, owing to the variable 
tumor microenvironments (Figure 1). This 
potential signaling cascade also elucidates 
the mechanism behind therapeutic benefits 
of STAT3 inhibition (13).
sTAT3 ANd ANTi-egFR TheRApy
miR-135b may also represent a mechanism 
by which a network of tumor suppressors 
is downregulated despite targeted therapy 
against the cancer cells. The most apparent 
example would be the upstream activation 
of STAT3 via epidermal growth factor recep-
tor regulation (EGFR). Multiple anti-EGFR 
drugs are utilized for treatment of HNSCC, 
bladder cancer, NSCLC, and colon cancer. 
The patients that qualify for this class of 
medications represent a selected group, and 
some continue to experience disease pro-
gression during treatment.
There is evidence that amongst HNSCC 
and NSCLC cells that are resistant to anti-
EGFR therapy, STAT3 remains persistently 
phosphorylated in its active state (15, 16). 
The presence of phosphorylated STAT3 sug-
gests a mode of activation that bypasses the 
EGFR signaling cascade (15). Concurrently, 
aggressive efforts are geared toward devel-
oping clinically available STAT3 inhibitors 
to restore the desired therapeutic effect or 
even replace anti-EGFR therapy (13, 16).
In treatment of colon cancer, anti-EGFR 
therapy is generally reserved for cases with-
out KRAS mutations (17). What remains to 
be understood is the role of phosphoryl-
ated STAT3 as a predictor of response to 
anti-EGFR therapy. In a recent retrospec-
tive study, investigators examined levels of 
phosphorylated STAT3 amongst patients 
receiving anti-EGFR therapy. Multivariate 
analysis demonstrated that absence of 
phosphorylated STAT3 was associated with 
improved overall survival and increase time 
to progression of the disease (18). This find-
ing suggests that if phosphorylated STAT3 is 
truly a marker of poor outcome,  mir-135b 
agent, suggesting a mode of epigenetic 
control in that cell population. Furthermore, 
investigators predicted that the transcription 
factor NF-κB has a potential binding site 
on the miR-135b promoter region (Figure 
1). After demethylation, TNFα, a known 
potentiator of NF-κB transcription, indeed 
increased expression of miR-135b, suggest-
ing a potential link between inflammatory 
signals and miR-135b transcription (4).
Interestingly, in the HNSCC study, 
miR-135b overexpression appeared to be 
induced from a knockdown of transforming 
growth factor beta receptor 1 (TGFBR1) (6). 
Clinically, mutations in TGFBR1 are associ-
ated with an increased risk of developing 
colon cancer (10).
In lymphoma cells, LEMD1 and miR-
135b expression were demonstrated to 
be under STAT3 regulation (11). Signal 
transducer and activator of transcription 
(STAT) proteins are a family of cytoplasmic 
transcription factors that mediate external 
cytokine signaling and growth factor stimu-
lation to transcription of genes involved in 
proliferation, differentiation, cell survival, 
development, and inflammation (12, 13). 
While there are several isoforms, constitu-
tive activation of STAT3 has been  identified 
through  deregulation of the β-catenin 
pathway. These mutations typically result 
from premature stop codons in the APC 
transcript and are detected in >70% of 
colon cancers. In cases where hypomorphic 
mutations are present, miR-135b activa-
tion may function as “third hit” to indeed 
suppress any residual tumor suppression 
(β-catenin regulating) activity. miR-135b 
expression is shown to be over 10-fold ele-
vated in carcinoma compared to normal 
colon epithelium and clearly associated 
with decreased APC expression irrespec-
tive of chromosomal mutations. This tight 
association is supported by confirmation 
of a miR-135b binding site at the APC 
3′ untranslated region and suggests that 
miR-135b upregulation leads to a more 
penetrant effect of APC derangement (7).
RegulATiON OF miR-135b expRessiON
miR-135b is encoded in the first intron of 
LEMD1 gene, a cancer/testis antigen shown 
to be aberrantly expressed in colon cancers 
(9). miR-135b is located on 1q32.1 which 
shows DNA copy number gain in CRC pro-
gression (7). Lung cancer lines demonstrate 
alteration of LEMD1 and miR-135b expres-
sion when treated with a  demethylating 
FiGuRE 1 | Schematic representation of miR-135b circuitry network. Studying the network 
surrounding miR-135b may elucidate links between otherwise far reaching pathways, such as EGFR/STAT3 
signaling to Hippo (LZTS1, LATS2) and inhibition of growth. miR-135b silencing in vivo may itself be 
therapeutic and understanding its function may uncover additional therapeutic targets.
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 miR-135b levels with better defined mark-
ers of stemness in colon cancer would be 
needed to provide conclusive evidence, and 
would be supported by differential expres-
sion of miR-135b along the crypt-villus axis.
cONclusiON
With the knowledge that we have about 
the regulation of miR-135b, its important 
downstream targets, and the oncogenic 
impact produced from its dysregulation, 
the data begs for more conclusive studies, 
particularly in vivo assessment of its role 
in colon cancer. miR-135b emerges as one 
example of a microRNA that may deepen 
our understanding of resistance to current 
cancer therapy, and possibly serve as an 
adjunct to guiding anti-EGFR treatment in 
colon cancer patients, particularly as its role 
is better explored in KRAS mutants. Direct 
blockade of miR-135b may itself serve as a 
therapeutic intervention against a network 
of events driving oncogenesis and even tar-
get the self-renewing CSCs. Understanding 
this valuable molecular target and plac-
ing it in our diagnostic and therapeutic 
armamentarium will enhance our options 
against colon and other cancers in an era of 
personalized medicine.
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pathway between malignancy derived from 
somatic mutations and those derived from 
inflammatory backgrounds where Wnt 
derangement is typically a later event. 
In vivo overexpression of miR-135b may 
help elucidate the role in tumorigenesis, 
particularly in the context of existing APC 
mutations and colitis models.
miR-135b iN cANceR sTeM cells
The role of miR-135b in cancer stem cells 
(CSCs) is also emerging and supported by 
the potential role of STAT3 in the same 
context. Through a screen for microRNAs 
deregulated in CSC in pediatric solid tumor 
lines, investigators identified miR-135b as 
highly expressed in the stem-cell enriched 
cell population (22). A stemness assay con-
firmed that in vitro blockade of miR-135b 
demonstrated a markedly diminished abil-
ity of the neuroblastoma and medulloblas-
toma cells to form neurospheres, thereby 
alluding to the role of miR-135b in self-
renewal and proliferation (22).
In colon cancer cell lines, investigators 
utilized CD133 and aldehyde dehydroge-
nase 1 (ALDH1) as selective markers for 
CSC and demonstrated increased ability of 
this selected cell population in producing 
subcutaneous tumors in xenograft models 
(23). This selected cell population demon-
strated increased levels of phosphorylated 
STAT3 compared to the unsorted cells. 
Furthermore, immunohistochemistry/
immunofluorescence analysis of over 100 
colon cancer microarrays demonstrated 
that co-localization of phosphorylated 
STAT3 and ALDH1 or CD133 occurred in 
over 60% of the cases. An anchorage-inde-
pendent assay showed that pharmacological 
inhibition of STAT3 in the CSCs mark-
edly decreased tumorsphere formation. 
Furthermore, treatment of the cell lines 
with STAT3 inhibitors decreased the per-
centage population of ALDH1+/CD133+ 
cells in contrast to treatment with doxoru-
bicin or 5-flurouracil which increased the 
ALDH1+/CD133+ subpopulation, suggest-
ing that STAT3 plays a unique role in CSC 
propagation.
The parallel findings of miR-135b 
suppression in pediatric CSC and STAT3 
blockade in colon CSC strongly allude to 
miR-135b as being an important driver 
in maintaining cell oncogenicity, particu-
larly in the self-renewing behaviors of 
CSCs. Further experimentation to assess 
also has the potential to be explored as 
a biomarker and driver of resistance to 
 anti-EGFR therapy.
Persistent STAT3 activation also has a 
specific association with cell proliferation 
and tumor growth in colon cancer. In a 
study of 32 tumor specimens, 29 demon-
strated STAT3 binding to DNA via elec-
trophoretic mobility shift assay (EMSA). 
Immunohistochemistry of colon cancer 
biopsies confirmed presence of phospho-
rylated STAT3 in the nuclei of dedifferen-
tiated epithelium but not in surrounding 
normal colonic crypts (14). When colon 
cancer cell lines were transfected with con-
stitutively active STAT3, cell proliferation 
was increased, whereas transformation of 
the cells with a dominant negative construct 
of STAT resulted in decreased proliferation.
This study also points to a potential limi-
tation of in vitro models in studying the role 
of phosphorylated STAT3, and presumably, 
miR-135b. In multiple colon cancer lines, 
investigators confirmed the abundance of 
STAT3 expression by Western Blot, similar 
to analysis of tumor specimens. However, 
when STAT3-DNA binding was assessed 
via EMSA, none of the cell lines demon-
strated constitutive binding. Upon treating 
the cells with interleukin-6 (IL-6), a known 
activator of the STAT3 pathway, constitu-
tive DNA binding was successfully demon-
strated. Similarly, when the cell lines were 
injected subcutaneously to produce xeno-
graft tumors where they were presumably 
exposed to in vivo paracrine and autocrine 
signaling, EMSA experiments confirmed 
abundance of DNA-bound STAT3.
These findings suggest that the tumor 
microenvironment plays an important role 
in inducing oncogenic signaling pathways. 
IL-6 levels are elevated in serum and tumor 
samples of multiple cancers, and IL-6 and 
STAT3 activation constitute an important 
pathway in tumorigenesis in colitis asso-
ciated cancers (19, 20). Moreover, miR-
135b expression was elevated in tumors in 
mouse models of APC mutations as well as 
inflammatory bowel disease (21). If miR-
135b expression is in fact tightly regulated 
by STAT3 in a variety of cancers, in vitro 
studies may be under-representing the 
degree of upregulation and oncogenicity 
that miR-135b contributes in vivo, particu-
larly in colon cancer and the subpopula-
tion of colitis associated cancers. miR-135b 
upregulation may be the common  initiating 
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